Breast cancer is the most commonly diagnosed malignancy and second leading cause of cancer death among American women. Mammography has contributed to early detection, and thus new treatments, of breast tumors, but has also generated controversies. Many patients now diagnosed at very early, symptom free stages of the disease may be likely candidates for breast-conserving treatment (BCT), but some will experience a morbid disease course and die if not promptly treated with radical intervention (mastectomy, chemo- and radiation therapies). Morphology-based histopathology has to date served effectively in assessing breast cancer patients, particularly in the age dominated by mastectomy, but it is insensitive in guiding treatment plans with BCT. In addition to morphological evaluation, a method that directly evaluates the biological behavior of individual tumors and predicts potential aggressiveness is now needed for optimal breast cancer management. To achieve this, we will test the efficacy of an ex vivo spectroscopic method of identifying cellular metabolic signatures. By providing a new paradigm for the biochemical diagnosis of breast cancer, this method can assist in the diagnosis and prognostication of breast tumors in the era of BCT. We will quantify cellular metabolic changes in the development and progression of breast cancer with high-resolution magic angle spinning (HRMAS) proton magnetic resonance spectroscopy (1HMRS). HRMAS 1HMRS can measure cellular metabolites in intact human tissue specimens, while preserving histopathological structures. We will test the ability of HRMAS 1HMRS to quantify breast cancer metabolites, correlate metabolic concentrations obtained with histopathological features measured in the same intact tissue samples, define and evaluate metabolic signatures for breast cancer according to type, grade and histopathologic stage, perform molecular biology analyses of tumor signatures at the cellular level with laser capture microdissection (LCM), reverse transcription polymerase chain reaction (RT-PCR), and establish biochemical databases that help predict tumor pathologies and patient outcome, independently of pathology. Initially, we will quantify tissue metabolites of new surgical specimens, as well as stored frozen tissues, with HRMAS 1HMRS. Observed metabolites that correlate with histopathology will then be used to create a database of breast cancer metabolite signatures. These signatures should be useful in clinical care of women with breast cancer by identifying less aggressive tumors as candidates for breast-conserving treatment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA095624-03
Application #
6892823
Study Section
Diagnostic Radiology Study Section (RNM)
Program Officer
Liu, Guoying
Project Start
2003-05-01
Project End
2007-04-30
Budget Start
2005-05-01
Budget End
2006-04-30
Support Year
3
Fiscal Year
2005
Total Cost
$287,613
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Jordan, Kate W; Adkins, Christen B; Cheng, Leo L et al. (2011) Application of magnetic-resonance-spectroscopy- based metabolomics to the fine-needle aspiration diagnosis of papillary thyroid carcinoma. Acta Cytol 55:584-9
Kaul, David; Wu, Chin-Lee; Adkins, Christen B et al. (2010) Assessing prostate cancer growth with mRNA of spermine metabolic enzymes. Cancer Biol Ther 9:736-42
Wu, Chin-Lee; Jordan, Kate W; Ratai, Eva M et al. (2010) Metabolomic imaging for human prostate cancer detection. Sci Transl Med 2:16ra8
Maxeiner, Andreas; Adkins, Christen B; Zhang, Yifen et al. (2010) Retrospective analysis of prostate cancer recurrence potential with tissue metabolomic profiles. Prostate 70:710-7
Jordan, K W; Adkins, C B; Su, L et al. (2010) Comparison of squamous cell carcinoma and adenocarcinoma of the lung by metabolomic analysis of tissue-serum pairs. Lung Cancer 68:44-50
Jordan, Kate W; Nordenstam, Johan; Lauwers, Gregory Y et al. (2009) Metabolomic characterization of human rectal adenocarcinoma with intact tissue magnetic resonance spectroscopy. Dis Colon Rectum 52:520-5
Loening, Nikolaus M; Chamberlin, Anne M; Zepeda, Andrea G et al. (2005) Quantification of phosphocholine and glycerophosphocholine with 31P edited 1H NMR spectroscopy. NMR Biomed 18:413-20
Burns, Melissa A; Taylor, Jennifer L; Wu, Chin-Lee et al. (2005) Reduction of spinning sidebands in proton NMR of human prostate tissue with slow high-resolution magic angle spinning. Magn Reson Med 54:34-42
Cheng, Leo L; Burns, Melissa A; Taylor, Jennifer L et al. (2005) Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy. Cancer Res 65:3030-4
Burns, Melissa A; He, Wenlei; Wu, Chin-Lee et al. (2004) Quantitative pathology in tissue MR spectroscopy based human prostate metabolomics. Technol Cancer Res Treat 3:591-8